Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHP681 in Healthy Adults
NCT03859323Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2019
- Primary completion
- Jan 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHP681 in short bowel syndrome (SBS) (13 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Number of Participants With Anti-drug Antibody. Started Mar 2019; status: completed.
02
Drugs
SHP681
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03859323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859323.